NCT05887492
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
- Study completion pushed from Sep 2026 to Nov 2026
- Primary completion date changed from estimate of Sep 2026 to Sep 22, 2026
- Secondary endpoints: details revised at 2 of 8 entries
- Site details revised at 1 of 13 sites
- Notable Primary and study completion dates pushed to Sep 2026
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 13 of 13 sites
- Minor Study sites: 11 to 13v16
- Minor Study sites: 10 to 11v15
- Notable Primary completion date: Jan 2025 to Jan 2026
- Study sites: 9 to 10
- Study completion date: Jun 2025 to Jun 2026
Show 9 earlier versionsHide 9 earlier versions
- Minor Study sites: 8 to 9v11
- Minor Study sites: 7 to 8v9
- Minor Study sites: 6 to 7v8
- Minor Study sites: 5 to 6v7
- Minor Study sites: 4 to 5v6
- Minor Study sites: 3 to 4v5
- Minor Study sites: 2 to 3v4
- Minor Study sites: 1 to 2
- Start date changed from estimate of Jun 2, 2023 to Jun 12, 2023
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date: Jul 2023 to Jun 2, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD
Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab
Drugs: TNG260, Pembrolizumab
Sites
13 sites in 1 country